Autoimmune heparin‐induced thrombocytopenia (aHIT) indicates the presence in patients of
anti‐platelet factor 4 (PF4)–polyanion antibodies that are able to activate platelets strongly …

Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy
caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic …

Key Clinical Points Heparin-Induced Thrombocytopenia Heparin-induced thrombocytopenia
(HIT) is characterized by a decrease in the platelet count of more than 50% from the highest …

Heparin has been recognized as a valuable anticoagulant and antithrombotic for several
decades and is still widely used in clinical practice for a variety of indications. The …

Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal,
immunologically mediated adverse drug reaction to unfractionated heparin or, less …

Heparin-induced thrombocytopenia is an immune-mediated disorder caused by antibodies
that recognize complexes of platelet factor 4 and heparin. Thrombosis is a central and …

Direct oral anticoagulants (DOACs) are attractive options for treatment of heparin-induced
thrombocytopenia (HIT). We report our continuing experience in Hamilton, ON, Canada …

Many drugs have been implicated in drug-induced immune thrombocytopenia (DITP).
Patients with DITP develop a drop in platelet count 5 to 10 days after drug administration …

Venous thromboembolism is a common and potentially life-threatening complication that
occurs in 4 to 15% of patients admitted to ICUs despite the routine use of pharmacological …

Heparin-induced thrombocytopenia (HIT) is an autoimmune thrombotic disorder caused by
immune complexes containing platelet factor 4 (PF4), antibodies to PF4 and heparin or …